Mexico approves emergency use of Pfizer-BioNTech coronavirus vaccine

Mexico is set to receive 250,000 doses of the vaccine, enough for 125,000 people.

The Mexican government's medical safety commission approved the emergency use of the Pfizer-BioNTech coronavirus vaccine, making Mexico the fourth country to do so.

Assistant Health Secretary Hugo Lpez-Gatell said Mexico's approval came on Friday after Britain, Canada and Bahrain.

Mexico is set to receive 250,000 doses of the vaccine, enough for 125,000 people, because each person requires two shots. Lpez-Gatell has said that front-line health workers will get the shots first.

Vaccinations are expected to begin as soon as next week. Lpez-Gatell said the approval is of course a reason for hope, though the initial rounds of shots are not nearly enough for Mexico's coronavirus cases Friday, for a total of 1,229,379 infections during the pandemic.

Officials also reported 693 more deaths related to COVID-19., bringing the country's total to 113,019. However, even official estimates place the real death toll at closer to 150,000, due to Mexico's extremely low level of testing.

Mexico City has become the central focus of increasing cases in the country. The capital's hospitals were 78% full Friday, a level that worried officials.

Mayor Claudia Sheinbaum issued an urgent appeal for residents of the capital to stay home, saying the city of almost 9 million was in a coronavirus emergency.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel